Why did the FDA walk back leucovorin autism claims?

FDA limits leucovorin to folate deficiency, not autism

Recent reporting says President Trump and Robert F. Kennedy Jr. touted leucovorin as a possible treatment for autism, and following the public push, outpatient prescriptions increased. However, the FDA later clarified the drug’s appropriate use: it approved leucovorin only for folate deficiency.

What happened

• Leucovorin entered the policy and media spotlight as a potential autism-related intervention.
• That attention was followed by a sharp rise in outpatient prescriptions.
• The FDA then “walked it back” by restricting the drug’s approval to its established indication.

Why this matters

This sequence highlights a recurring public health challenge: when influential figures promote an unproven or off-label hypothesis, demand for the medication can surge quickly—creating risk that patients receive drugs for claims that are not supported by regulatory approval.

It also underscores the FDA’s role in separating marketing or advocacy from evidence-based indications. By reaffirming that leucovorin is approved for folate deficiency, regulators drew a line around what clinicians can prescribe with an indication supported by the agency.

The bottom line

Leucovorin may have legitimate medical use when folate deficiency is present, but it is not an FDA-approved autism treatment. Patients and families considering it should be cautious and rely on clinicians for evidence-based guidance rather than political messaging.